Shares of Hill-Rom Holdings Inc. (NYSE:HRC) hit a new 52-week high during trading on Tuesday . The stock traded as high as $58.92 and last traded at $58.50, with a volume of 267,195 shares traded. The stock had previously closed at $58.04.

Several brokerages have commented on HRC. Bank of America Corp. reaffirmed a “buy” rating and issued a $69.00 price objective on shares of Hill-Rom Holdings in a research report on Monday, May 2nd. Morgan Stanley reaffirmed a “hold” rating on shares of Hill-Rom Holdings in a research report on Tuesday, May 3rd. Zacks Investment Research raised shares of Hill-Rom Holdings from a “hold” rating to a “buy” rating and set a $64.00 price objective on the stock in a research report on Tuesday, August 9th. Finally, KeyCorp reaffirmed a “buy” rating and issued a $59.00 price objective on shares of Hill-Rom Holdings in a research report on Thursday, June 23rd. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Hill-Rom Holdings has a consensus rating of “Buy” and a consensus target price of $61.50.

The stock’s 50 day moving average is $53.83 and its 200-day moving average is $50.28. The firm has a market cap of $3.83 billion and a P/E ratio of 60.18.

Hill-Rom Holdings (NYSE:HRC) last announced its quarterly earnings data on Thursday, August 4th. The medical technology company reported $0.81 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.76 by $0.05. During the same period last year, the company posted $0.62 earnings per share. The firm had revenue of $655.40 million for the quarter, compared to analysts’ expectations of $647.75 million. The business’s revenue for the quarter was up 38.1% compared to the same quarter last year. On average, equities research analysts expect that Hill-Rom Holdings Inc. will post $3.33 EPS for the current year.

A number of hedge funds have recently made changes to their positions in HRC. Matarin Capital Management LLC purchased a new stake in shares of Hill-Rom Holdings during the fourth quarter valued at approximately $5,230,000. Trexquant Investment LP bought a new stake in shares of Hill-Rom Holdings during the fourth quarter worth about $1,662,000. Marshall Wace LLP bought a new stake in shares of Hill-Rom Holdings during the fourth quarter worth about $1,674,000. Finally, Morgan Stanley increased its stake in shares of Hill-Rom Holdings by 203.0% in the fourth quarter. Morgan Stanley now owns 467,877 shares of the medical technology company’s stock worth $22,486,000 after buying an additional 313,445 shares during the last quarter.

Hill-Rom Holdings, Inc is a medical technology company. The Company offers patient care solutions that improve clinical and economic outcomes in advancing mobility, wound care and prevention, clinical workflow, surgical safety and efficiency, and respiratory health areas. Its segments include North America, Surgical and Respiratory Care, International and Welch Allyn.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.